In Reply - Immune Checkpoint Inhibitor-Induced Type 1 Diabetes: An Underestimated Risk

Mayo Clin Proc. 2020 Mar;95(3):615. doi: 10.1016/j.mayocp.2019.12.010.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents, Immunological*
  • Diabetes Mellitus, Type 1*
  • Humans
  • Immunologic Factors
  • Nivolumab

Substances

  • Antineoplastic Agents, Immunological
  • Immunologic Factors
  • Nivolumab